NCT05150691 2026-01-28
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
DualityBio Inc.
DualityBio Inc.
Jiangsu HengRui Medicine Co., Ltd.
Daiichi Sankyo
Philogen S.p.A.
Philogen S.p.A.
Abbott